JSPR (Jasper Therapeutics) Tariff Resilience Score: 7/10 (As of Jul. 05, 2026)


JSPR Jasper Therapeutics Inc JSPR
29 GF Score
Price $0.43
! 1 Warning Sign
View Full Analysis

What is Jasper Therapeutics Tariff Resilience Score?

Jasper Therapeutics JSPR -5.19% 29 Tariff Resilience Score is 7 as of Jul. 05, 2026. GuruFocus rates JSPR with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,369 Biotechnology companies, Jasper Therapeutics ranks better than 90.36% on this metric.

Jasper Therapeutics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Jasper Therapeutics has Biotechnology firm with limited direct exposure to tariffs. Potential vulnerabilities exist if expanding manufacturing or sales internationally, but current focus is primarily domestic.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Jasper Therapeutics might have Highly Resilient.

Jasper Therapeutics  (NAS:JSPR) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Jasper Therapeutics Tariff Resilience Score Related Terms

JSPR vs CVKD, BRTX, APRE: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Jasper Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jasper Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jasper Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Jasper Therapeutics's Tariff Resilience Score falls into.


JSPR
29GF Score
Jasper Therapeutics Inc JSPR
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Jasper Therapeutics (JSPR) has a Tariff Resilience Score of 7 as of Jul. 05, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Jasper Therapeutics ranks #132 out of 1369 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Jasper Therapeutics' Tariff Resilience Score too high?
Jasper Therapeutics' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Jasper Therapeutics' value of 7 is 75% above this industry median. Based on the distribution chart, Jasper Therapeutics ranks #132 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jasper Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Jasper Therapeutics' Tariff Resilience Score compare to CVKD and BRTX?
According to the Biotechnology industry distribution chart, Jasper Therapeutics ranks #132 out of 1369 companies for Tariff Resilience Score. This places Jasper Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Jasper Therapeutics' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jasper Therapeutics's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jasper Therapeutics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jasper Therapeutics stock overvalued right now?
Jasper Therapeutics (JSPR) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Jasper Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Jasper Therapeutics (JSPR), the current Tariff Resilience Score is 7 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jasper Therapeutics Business Description

Address 2200 Bridge Parkway, Suite 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
29GF Score

Get the complete analysis for JSPR

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.43
Price